A CLINICAL EVALUATION OF PIPERACETAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA
Abstract
This study indicates that Quide is a useful addition to the armamentarium of the physician faced with the difficult problem of treating the chronic hospitalized patient with a schizophrenic illness. Side effects of the drug were generally mild, and there was no evidence that it would produce blood dyscrasias or liver impairment.
As a result of the circumscribed nature of this study it would be difficult to determine the long-term effects of the drug. However, the drug has shown no chronic untoward effects in previous studies and no chronic effects from the drug were expected. At the end of the study most of the patients were removed from maintenance doses of the drug. Of the total group one patient was discharged on an indefinite furlough. Another was discharged on a temporary furlough. The remainder of the patients in the study continued in the hospital.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
